Higher patient perceived side effects related to higher daily doses of inhaled corticosteroids in the community: A cross-sectional analysis

Juliet Foster, Lorna Sharman Aucott, R. van der Werf, M. van der Meijden, G. Schraa, Thys Van Der Molen

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

The range and extent of inhaled corticosteroid (ICS) side effects experienced by patients in the general community are likely to be underestimated. AIMS: To identify the side effects of ICS perceived by patients in the community and, through the use of a self-report questionnaire, measure their intensity, prevalence and relationship with daily medication dose. METHODS: Focus groups and in-depth interviews were conducted to identify side effects that patients associated with their use of ICS. In an international multicentre cross-sectional survey, 395 inhaler users from community pharmacy (mean age 50, 53% female), divided into 4 daily dosage groups (beta2-agonist without ICS n=66, beclometasone dipropionate (BDP) equivalent ICS low dose 400 microg, n=109; mid dose 401-800 microg, n=151; and high dose>800 microg, n=69) reported how much they were affected by these side effects on a 7-point Likert scale. RESULTS: Focus groups and interviews revealed 57 side effects that were associated with ICS use. Cross-sectional survey results showed significant differences in side effect perception between the four dosage groups for 31 items (all P0.01) and a rising intensity with increasing ICS dose for total side effect score (P<0.001). For ICS users reporting the most bothersome side effects (scoring 3 on 0-6 scale) there was a rising prevalence as ICS dose increased for 34 items. A multivariate model confirmed that mid and high ICS dosages were statistically significantly associated with side effect perception after controlling for the other factors and covariates. CONCLUSIONS: Higher daily ICS doses were associated with a higher intensity and a higher prevalence of many patient perceived side effects, lending support to the call for dose titration in clinical practice. Results indicate the usefulness of patient self-report scales for understanding the burden of side effects of ICS in the community.
Original languageEnglish
Pages (from-to)1318-36
Number of pages19
JournalRespiratory Medicine
Volume100
Issue number8
Early online date25 Jan 2006
DOIs
Publication statusPublished - Aug 2006

Fingerprint

Adrenal Cortex Hormones
Cross-Sectional Studies
Focus Groups
Self Report
Interviews
Beclomethasone
Pharmacies
Nebulizers and Vaporizers

Cite this

Higher patient perceived side effects related to higher daily doses of inhaled corticosteroids in the community: A cross-sectional analysis. / Foster, Juliet; Aucott, Lorna Sharman; van der Werf, R.; van der Meijden, M.; Schraa, G.; Van Der Molen, Thys.

In: Respiratory Medicine, Vol. 100, No. 8, 08.2006, p. 1318-36.

Research output: Contribution to journalArticle

Foster, Juliet ; Aucott, Lorna Sharman ; van der Werf, R. ; van der Meijden, M. ; Schraa, G. ; Van Der Molen, Thys. / Higher patient perceived side effects related to higher daily doses of inhaled corticosteroids in the community: A cross-sectional analysis. In: Respiratory Medicine. 2006 ; Vol. 100, No. 8. pp. 1318-36.
@article{2ce2e1f3dc734c1a8257c021ea8c0d5f,
title = "Higher patient perceived side effects related to higher daily doses of inhaled corticosteroids in the community: A cross-sectional analysis",
abstract = "The range and extent of inhaled corticosteroid (ICS) side effects experienced by patients in the general community are likely to be underestimated. AIMS: To identify the side effects of ICS perceived by patients in the community and, through the use of a self-report questionnaire, measure their intensity, prevalence and relationship with daily medication dose. METHODS: Focus groups and in-depth interviews were conducted to identify side effects that patients associated with their use of ICS. In an international multicentre cross-sectional survey, 395 inhaler users from community pharmacy (mean age 50, 53{\%} female), divided into 4 daily dosage groups (beta2-agonist without ICS n=66, beclometasone dipropionate (BDP) equivalent ICS low dose 400 microg, n=109; mid dose 401-800 microg, n=151; and high dose>800 microg, n=69) reported how much they were affected by these side effects on a 7-point Likert scale. RESULTS: Focus groups and interviews revealed 57 side effects that were associated with ICS use. Cross-sectional survey results showed significant differences in side effect perception between the four dosage groups for 31 items (all P0.01) and a rising intensity with increasing ICS dose for total side effect score (P<0.001). For ICS users reporting the most bothersome side effects (scoring 3 on 0-6 scale) there was a rising prevalence as ICS dose increased for 34 items. A multivariate model confirmed that mid and high ICS dosages were statistically significantly associated with side effect perception after controlling for the other factors and covariates. CONCLUSIONS: Higher daily ICS doses were associated with a higher intensity and a higher prevalence of many patient perceived side effects, lending support to the call for dose titration in clinical practice. Results indicate the usefulness of patient self-report scales for understanding the burden of side effects of ICS in the community.",
author = "Juliet Foster and Aucott, {Lorna Sharman} and {van der Werf}, R. and {van der Meijden}, M. and G. Schraa and {Van Der Molen}, Thys",
year = "2006",
month = "8",
doi = "10.1016/j.rmed.2005.11.029",
language = "English",
volume = "100",
pages = "1318--36",
journal = "Respiratory Medicine",
issn = "0954-6111",
publisher = "Elsevier",
number = "8",

}

TY - JOUR

T1 - Higher patient perceived side effects related to higher daily doses of inhaled corticosteroids in the community: A cross-sectional analysis

AU - Foster, Juliet

AU - Aucott, Lorna Sharman

AU - van der Werf, R.

AU - van der Meijden, M.

AU - Schraa, G.

AU - Van Der Molen, Thys

PY - 2006/8

Y1 - 2006/8

N2 - The range and extent of inhaled corticosteroid (ICS) side effects experienced by patients in the general community are likely to be underestimated. AIMS: To identify the side effects of ICS perceived by patients in the community and, through the use of a self-report questionnaire, measure their intensity, prevalence and relationship with daily medication dose. METHODS: Focus groups and in-depth interviews were conducted to identify side effects that patients associated with their use of ICS. In an international multicentre cross-sectional survey, 395 inhaler users from community pharmacy (mean age 50, 53% female), divided into 4 daily dosage groups (beta2-agonist without ICS n=66, beclometasone dipropionate (BDP) equivalent ICS low dose 400 microg, n=109; mid dose 401-800 microg, n=151; and high dose>800 microg, n=69) reported how much they were affected by these side effects on a 7-point Likert scale. RESULTS: Focus groups and interviews revealed 57 side effects that were associated with ICS use. Cross-sectional survey results showed significant differences in side effect perception between the four dosage groups for 31 items (all P0.01) and a rising intensity with increasing ICS dose for total side effect score (P<0.001). For ICS users reporting the most bothersome side effects (scoring 3 on 0-6 scale) there was a rising prevalence as ICS dose increased for 34 items. A multivariate model confirmed that mid and high ICS dosages were statistically significantly associated with side effect perception after controlling for the other factors and covariates. CONCLUSIONS: Higher daily ICS doses were associated with a higher intensity and a higher prevalence of many patient perceived side effects, lending support to the call for dose titration in clinical practice. Results indicate the usefulness of patient self-report scales for understanding the burden of side effects of ICS in the community.

AB - The range and extent of inhaled corticosteroid (ICS) side effects experienced by patients in the general community are likely to be underestimated. AIMS: To identify the side effects of ICS perceived by patients in the community and, through the use of a self-report questionnaire, measure their intensity, prevalence and relationship with daily medication dose. METHODS: Focus groups and in-depth interviews were conducted to identify side effects that patients associated with their use of ICS. In an international multicentre cross-sectional survey, 395 inhaler users from community pharmacy (mean age 50, 53% female), divided into 4 daily dosage groups (beta2-agonist without ICS n=66, beclometasone dipropionate (BDP) equivalent ICS low dose 400 microg, n=109; mid dose 401-800 microg, n=151; and high dose>800 microg, n=69) reported how much they were affected by these side effects on a 7-point Likert scale. RESULTS: Focus groups and interviews revealed 57 side effects that were associated with ICS use. Cross-sectional survey results showed significant differences in side effect perception between the four dosage groups for 31 items (all P0.01) and a rising intensity with increasing ICS dose for total side effect score (P<0.001). For ICS users reporting the most bothersome side effects (scoring 3 on 0-6 scale) there was a rising prevalence as ICS dose increased for 34 items. A multivariate model confirmed that mid and high ICS dosages were statistically significantly associated with side effect perception after controlling for the other factors and covariates. CONCLUSIONS: Higher daily ICS doses were associated with a higher intensity and a higher prevalence of many patient perceived side effects, lending support to the call for dose titration in clinical practice. Results indicate the usefulness of patient self-report scales for understanding the burden of side effects of ICS in the community.

U2 - 10.1016/j.rmed.2005.11.029

DO - 10.1016/j.rmed.2005.11.029

M3 - Article

VL - 100

SP - 1318

EP - 1336

JO - Respiratory Medicine

JF - Respiratory Medicine

SN - 0954-6111

IS - 8

ER -